RINGPU(300119) 中证网·2025-04-09 08:37Group 1 - The company reported an operating income of 3.07 billion yuan, a year-on-year increase of 13.32% [1] - The net profit attributable to shareholders was 301 million yuan, with a proposed cash dividend of 3 yuan per 10 shares (tax included) [1] - Research and development investment reached 238 million yuan, accounting for 7.76% of operating income, with 10 new veterinary drug registration certificates and 29 authorized patents obtained [1] Group 2 - Breakthroughs were achieved in the biopharmaceutical field, including advancements in mRNA technology platforms and recombinant duck plague virus vector vaccines [1] - The self-developed cat trivalent vaccine "Rui Miao Shu" became the first domestically listed product [1] - The developed micro-coated preparation of enrofloxacin hydrochloride reduced medication costs by 25%-50%, receiving high industry recognition [1] Group 3 - The company completed the registration of 35 products, with Tianjin and High-Tech companies passing Indonesia's GMP audit, and Biwei Antai obtaining Thailand's GMP certification [1] - Collaborations were established with over 20 group clients for million-level partnerships, creating 50 million-level flagship products [1] - Strategic partnerships were deepened with leading enterprises such as Dekang Animal Husbandry and Shengnong Development, building an industrial ecosystem [1] Group 4 - Looking ahead, the company will continue to deepen research and development in mRNA, genetic engineering vaccines, and innovative drugs [2] - The company aims to accelerate its layout in the pet and ruminant sectors, constructing a full chain of "research-development-production-service" [2] - Key products, processes, and technologies will be targeted for mergers and acquisitions to enhance product competitiveness and market share [2]